348 related articles for article (PubMed ID: 16601536)
1. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
2. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
4. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
5. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
6. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
8. Intravenous neridronate in adults with osteogenesis imperfecta.
Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
[TBL] [Abstract][Full Text] [Related]
9. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
13. Oral alendronate in osteogenesis imperfecta.
Unal E; Abaci A; Bober E; Buyukgebiz A
Indian Pediatr; 2005 Nov; 42(11):1158-60. PubMed ID: 16340059
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of oral alendronate in the treatment of pediatric osteogenesis imperfecta].
Wei SS; Cai QX; Qiu WJ; Zhao L; Ye J; Wang XL; Chen Q; Gu XF
Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(4):246-9. PubMed ID: 22490796
[TBL] [Abstract][Full Text] [Related]
15. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
Marini JC; Hopkins E; Glorieux FH; Chrousos GP; Reynolds JC; Gundberg CM; Reing CM
J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
[TBL] [Abstract][Full Text] [Related]
16. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
[TBL] [Abstract][Full Text] [Related]
17. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
Saganelidze KhZ
Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
[TBL] [Abstract][Full Text] [Related]
18. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
19. The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
Atamaz F; Hepguler S; Karasu Z; Kilic M; Tokat Y
Transplant Proc; 2006 Jun; 38(5):1448-52. PubMed ID: 16797329
[TBL] [Abstract][Full Text] [Related]
20. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
